The monoamine oxidase-B inhibitor selegiline does not affect 18F-Florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series
Objective: In a longitudinal case series of patients with progressive supranuclear palsy (PSP), a chronic challenge with the irreversible MAO-B inhibitor selegiline was used to…Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease
Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…The role of Anti-Ribosomal P antibody in Autoimmune cerebellar ataxia
Objective: To describe the clinical features and presentation of an auto-immune cerebellar ataxia with asymmetric Holmes tremor and its therapeutic response. Background: Autoimmune cerebellar ataxia…The added value of accelerometric monitoring during thalamotomy
Objective: To quantify the clinical changes in tremor during the different stages of thalamotomy, and to investigate the relationship between intraoperative findings and clinical outcome.…Safety of foslevodopa/foscarbidopa during optimization and maintenance treatment: Post hoc analysis of a phase 3, single-arm trial
Objective: Evaluate the frequency of adverse events over time with foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (PD) in a phase 3, open-label safety…Prevalence of cardiovascular drugs and oral anticoagulants use among persons with and without Parkinson’s disease
Objective: We investigated prevalence of Cardiovascular drugs and Oral anticoagulants (OAC) use among community-dwelling persons with and without Parkinson's disease (PD) in relation to PD…Progressive Supranuclear Palsy: Review On Diagnostic Aspects Based On A Case
Objective: This article was written to enrich the spectrum of PSP case reports, emphasizing the diagnosis aspect. Background: Progressive supranuclear palsy (PSP) is the main…The effect of APOE ε4 on striatal vesicular monoamine transporter-2 density in Parkinson’s disease
Objective: To evaluate the effect of apolipoprotein E 4 (APOE 4) on striatal vesicular monoamine transporter-2 (VMAT2) density in Parkinson’s disease (PD).To evaluate the effect…Foslevodopa/foscarbidopa in patients with advanced Parkinson’s disease: subgroup analyses from a phase 3, randomized study
Objective: Present the efficacy and safety of 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDP/CDP) across pre-specified subgroups (age, sex, body mass index [BMI], race,…Combined approach in the diagnostic of Parkinson’s disease
Objective: Our aim was to develop and scientifically substantiate set of criteria for early(preclinical) diagnosis of neurodegenerative disorders with the assessment of a number of…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 1374
- Next Page »